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Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is
inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based chemotherapy (CT) sensitivity in
combination with KRAS mutations that have been associated with cetuximab resistance. KRAS and TP53 status were assessed in
tumours from 64 metastatic colorectal cancer patients treated with cetuximab-based CT and correlated to clinical response using the
Fisher’s exact test. Times to progression (TTPs) according to gene status were calculated using the Kaplan–Meier method and
compared with log-rank test. TP53 mutations were found in 41 patients and were significantly associated with controlled disease
(CD), as defined as complete response, partial response or stable disease (P¼0.037) and higher TTP (20 vs 12 weeks, P¼0.004).
Remarkably, in the subgroup of 46 patients without KRAS mutation, but not in patients with KRAS mutation, TP53 mutations were also
associated with CD (P¼0.008) and higher TTP (24 vs 12 weeks, P¼0.0007). This study suggests that TP53 mutations are predictive
of cetuximab sensitivity, particularly in patients without KRAS mutation, and that TP53 genotyping could have a clinical interest to
select patients who should benefit from cetuximab-based CT.
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In the past decade, the development of new combinations of
conventional chemotherapies (CTs) and the introduction of
targeted therapies have led to a dramatic improvement of the
overall survival of patients with metastatic colorectal cancer
(MCRC) (Meyerhardt and Mayer, 2005). Nevertheless, the
variability of the response rates in MCRC patients treated with
anti-EGFR in monotherapy or in association with CT underlines
the urgent need of predictive markers to select the appropriate
patients who can benefit from these treatments (Cunningham et al,
2004; Saltz et al, 2004; Jonker et al, 2007; Van Cutsem et al, 2007).
Anti-EGFR antibodies used in MCRC, such as cetuximab and
panitumumab, are predicted to bind to the EGFR ectodomain,
which prevents ligand fixation and therefore inhibits EGFR-
dependent transduction cascades such as the RAS–RAF–MEK–
MAPK and PIK3CA–Akt pathways (Ciardello and Tortora, 2008).
From a theoretical point of view, anti-EGFR cancer treatment
requires three parameters to be efficient. First, activation of the
EGFR pathway should contribute to the malignant transformation.
Although the mechanisms of this activation have not been clearly
established in colorectal cancer (CRC), it could result from gain of
copies of the EGFR gene, or overexpression of EGFR ligands that
have both been suggested to be markers of sensitivity to anti-EGFR
(Moroni et al, 2005; Sartore-Bianchi et al, 2005; Khambata-Ford
et al, 2007; Cappuzzo et al, 2008a; Personeni et al, 2008). Second,
activation of the EGFR pathway should not result from the
activation of a downstream EGFR effector such as RAS or PI3KCA.
Indeed several recent studies in MCRC patients have unambigu-
ously established that the presence of a somatic KRAS activating
mutation is highly predictive of resistance to anti-EGFR antibodies
(Lie `vre et al, 2006, 2008; Benvenuti et al, 2007; Di Fiore et al, 2007;
Khambata-Ford et al, 2007; Amado et al, 2008; De Roock et al,
2008; Karapetis et al, 2008; Van Cutsem et al, 2008). Besides KRAS
mutation, it has been recently reported that loss of PTEN
expression/PI3KCA activation and BRAF mutations are also
associated with resistance to anti-EGFR (Benvenuti et al, 2007;
Frattini et al, 2007; Cappuzzo et al, 2008b; Di Nicolantonio et al,
2008; Jhawer et al, 2008; Perrone et al, 2009). Last, several data
suggest that molecular brakes such as p53, protecting the cells
against inappropriate oncogene activation should be inactivated.
Indeed, recent studies have indicated that oncogenic activation of
transduction cascades leads to malignant transformation, only if
p53 is inactivated: alteration of the p53 pathway has been reported
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sto be systematically observed in NSCLC with activating EGFR
mutations suggesting that p53 inactivation is required to allow
expansion of a cell with EGFR pathway activation (Mounawar et al,
2007). Moreover, it has been shown that activation of PIK3CA
signalling activates p53-mediated growth suppression, suggesting
that p53 acts as a brake for the activated PIK3CA transduction
cascade (Kim et al, 2007).
This observation led us to hypothesise that, among MCRC
without KRAS mutation, tumours with TP53 mutations should be
more sensitive to anti-EGFR antibodies. We therefore evaluate in
this study the combined impact of KRAS and TP53 status on
clinical outcome in MCRC patients treated with cetuximab.
MATERIALS AND METHODS
Patients
We assessed 64 chemorefractory MCRC patients treated with
cetuximab-based CT and for whom tumour tissues were available
for molecular analysis. Among these patients, 44 patients had
already been included in a previous study focused on the impact of
KRAS status on the clinical response to cetuximab (Di Fiore et al,
2007). Tumour response was evaluated according to the response
evaluation criteria in solid tumours (Therasse et al, 2000). Patient
tumour response was classified as complete response (CR), partial
response (PR), stable disease (SD) or progressive disease (PD).
Patients with CR or PR or SD were considered as patients with
controlled disease (CD). Follow-up was performed on clinical basis
and CT scan until disease progression, death or the last follow-up
at which point data were censored.
DNA extraction
For 55 patients, DNA was extracted from paraffin-embedded
tumour tissue. After macrodissection, the extraction was carried
out using the DNA extraction kits from Takara (Madison, WI,
USA) or Ambion (Huntingdon, Cambridgeshire, UK), according to
the manufacturer’s instructions. For the nine remaining patients,
DNA was extracted from frozen samples using the QIAamp DNA
mini kit (Qiagen, Courtaboeuf, France). For each tumour sample,
the percentage of malignant cells was estimated, by morphological
analysis, to at least 50%.
KRAS and TP53 genotyping
For all patients, KRAS mutation analysis was performed using the
SNaPshot multiplex assay, as previously described (Di Fiore et al,
2007). TP53 exons 5–8 were PCR amplified from tumour DNA
(primer sequences are available upon request), and after purifica-
tion using the NucleoSpin Extract II kits (Masherey Nagel, Du ¨ren,
Germany), PCR products were sequenced using the BigDye
Terminator v3.1 kit (Applied Biosystems, Foster City, CA, USA)
and a 3130xl Genetic Analyzer (Applied Biosystems). For nine
patients, DNA was extracted from frozen tissue allowing the
screening of mutations by high resolution melting analysis using
the LightScanner instrument from Idaho Technology (Salt Lake
City, UT, USA). For these nine patients, only the amplicons with an
aberrant denaturation curve were sequenced. For the 55 remaining
samples, DNA was extracted from paraffin-embedded tumour
tissue and TP53 mutations were detected by direct sequencing.
Considering the presence of non-malignant cells in tumour
samples, the presence of a TP53 mutation in the tumour was
defined as the appearance of a mutant peak with a height of at least
25% of the wild type, and each detected TP53 mutation was
confirmed by a second sequencing analysis performed on an
independent PCR. For both KRAS and TP53 mutational analyses,
data were analysed without knowing the clinical response of
patients.
Statistical analysis
Response to treatment according to the mutational status was
evaluated using the Fisher’s exact test. The time to progression
(TTP) was calculated as the period from the beginning of
treatment to the first observation of disease progression or to
death or the last follow-up at which point data were censored. The
TTPs were estimated using the Kaplan–Meier method and
compared with the log-rank test. Multivariate analysis of predictive
factors of TTP was performed using a Cox regression model with
calculation of hazard ratio (HR) and a confidence interval (CI) of
95%. A P-value p0.05 was considered to indicate statistical
significance. All statistics were calculated using the StatView
statistical software (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient characteristics and outcome
A total of 64 chemorefractory MCRC patients treated with
cetuximab-based CT, including 45 men and 19 women with a
mean age of 59.5 years (range 20–82; s.d. 12.8), were included in
this study (Table 1). Patients had received a mean of 1.9 previous
metastatic CT lines before cetuximab and 90% of them were
irinotecan refractory. Sixty-two patients received cetuximab with
irinotecan-based CT, one received cetuximab with combined
irinotecan and oxaliplatin-based CT and one received cetuximab
alone. Response to cetuximab-based CT showed that 39 patients
(61%) had a CD (2 CR, 14 PR and 23 SD) whereas 25 were in PD
(39%). The median TTP was 24 weeks in patients with CD vs 12
weeks in patients with PD (Po0.0001).
Table 1 Patients characteristics according to their TP53 and KRAS mutational status
All (n¼64) KRAS non-mutated (n¼46)
TP53 TP53
Mutated Non-mutated P Mutated Non-mutated P
Sex ratio (men/women) 2.25 2 NS 2.22 1.8 NS
Age X70 years (%) 24.4 23.8 NS 26.7 28.6 NS
Irinotecan-refractory patients (%) 90 90 NS 93 100 NS
42 previous metastatic CT lines (%) 10 10 NS 13.8 7.7 NS
Mean of previous metastatic CT lines 1.91 1.92 NS 1.92 1.91 NS
CT¼chemotherapy; NS¼not significant.
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A KRAS mutation was found in 18 patients (28%). As presented in
Table 2, the three most frequent mutations were c.35G4T,
c.38G4A and c.35G4A. None of the 16 patients with CR or PR
had a KRAS mutation. In contrast, 7 out of 23 (30%) patients with
SD and 11 out of 25 (44%) with PD had a KRAS mutation
respectively. Using the Fisher’s exact test, we found that KRAS
mutations were significantly associated with PD vs CD (P¼0.044).
The median TTP of patients with KRAS mutation was significantly
lower as compared to those with wild-type KRAS (12 vs 20 weeks,
P¼0.034).
TP53 mutational status and clinical outcome
A total of 46 TP53 mutations were found in 41 out of 64 patients
(64%). Recurrent mutations were found at codons 152, 175,
213, 245, 248, 273 and 282 as presented in Table 2.
No significant difference was found for the main clinical
characteristics between patients with and without TP53 mutation
(Table 1). A TP53 mutation was detected in 29 out of 39 patients
with CD (74%) and in 12 out of 25 patients with PD (48%). TP53
mutations were significantly associated with CD vs PD (P¼0.037;
Table 3). Moreover, median TTP in patients with TP53 mutation
was significantly increased as compared to patients without
detectable TP53 mutation (20 vs 12 weeks, P¼0.004).
Combined KRAS and TP53 status and clinical outcome
Considering the hypothesis of this study, we then focused our
analysis on the subgroup of 46 patients without KRAS mutation. In
this subgroup, we detected a TP53 mutation in 30 patients (65.2%;
Table 4). The main clinical characteristics between patients with
and without TP53 mutation were not significantly different
(Table 1). A TP53 mutation was found in 25 out of 32 (78%)
patients with CD as compared to 5 out of 14 (36%) with PD
(P¼0.008; Table 4). In patients with wild-type KRAS , those having
TP53 mutation had a significantly higher TTP as compared to
those without detectable TP53 mutation (24 vs 12 weeks,
P¼0.0007; Figure 1A). In contrast, in the subgroup of patients
with KRAS mutation, the median TTPs were not different between
patients with and without TP53 mutation (Figure 1B).
Multivariate analysis
A Cox regression model was performed to determine the predictive
factor of TTP in the whole population. This analysis included the
following variables: sex, age X70 years, previous metastatic CT
lines 42, KRAS and TP53 status. TP53 mutations and KRAS
mutations were identified as two independent predictive factors
(HR¼1.99, 95% CI 1.09–3.63, P¼0.024 and HR¼0.48, 95% CI
0.25–0.94, P¼0.032 respectively).
DISCUSSION
KRAS mutation has been reported in several studies as a predictive
marker of anti-EGFR resistance in MCRC (Lie `vre et al, 2006, 2008;
Benvenuti et al, 2007; Di Fiore et al, 2007; Khambata-Ford et al,
2007; Amado et al, 2008; De Roock et al, 2008; Karapetis et al,
2008; Van cutsem et al, 2008) and the characterisation of other
parameters underlying the response variability to anti-EGFR is
now an important issue. Investigation in this MCRC patients series
of other markers, which had previously been shown to be
associated either to sensitivity or resistance to anti-EGFR
antibodies, revealed a BRAF mutation in 2 out of 49 (4%) patients
(these patients having no detectable KRAS mutation and present-
ing an SD), a PIK3CA mutation in 5 out of 45 (11%) patients (2 out
of 27 patients with CD and 3 out of 18 patients with PD) and an
EGFR gene copy number increase, as defined by a number of EGFR
per nucleus above 2.5 in 40% of the cells, in 9 out of 47 (19%)
tumours (2 tumours with CR, 2 with PR and 3 being stabilised and
the last one, which progressed under cetuximab-based therapy,
was found to have a KRAS mutation). Although the frequency of
these alterations is in agreement with the published studies
(Moroni et al, 2005; Sartore-Bianchi et al, 2005; Lie `vre et al, 2006,
2008; Benvenuti et al, 2007; Khambata-Ford et al, 2007; Cappuzzo
et al, 2008a,b; Di Nicolantonio et al, 2008; Personeni et al, 2008;
Perrone et al, 2009), indicating that our series is representative of
MCRC, these alterations did not appear statistically associated with
clinical outcome to cetuximab-based CT, considering the sample
size. In contrast, this study, performed in 64 MCRC patients,
suggests that TP53 mutations are predictive markers of cetuximab
sensitivity, particularly in the subgroup of patients without
detectable KRAS mutation. Indeed, our results showed that TP53
mutations, in patients with wild-type KRAS, were associated with a
higher CD and TTP (Table 4; Figure 1A), and the multivariate
Table 2 Distribution of KRAS and TP53 mutations
Mutation
Predicted effect on
protein Location
Number of
samples
a
KRAS mutations
c.34G4T p.G12C Exon 2 2
c.34G4A P.G12S Exon 2 1
c.35G4T p.G12V Exon 2 5
c.35G4A p.G12D Exon 2 3
c.35G4C p.G12A Exon 2 1
c.37G4T p.G13C Exon 2 1
c.38G4A p.G13D Exon 2 5
TP53 mutations
c.379T4C p.Ser127Pro Exon 5 1
c.382_423del p.Ala129_Pro142del Exon 5 1
c.404G4T p.Cys135Phe Exon 5 1
c.449_461del p.Pro152AlafsX14 Exon 5 1
c.455C4T p.Pro152Leu Exon 5 2
c.455dup p.Pro153AlafsX28 Exon 5 1
c.458C4T p.Pro153Leu Exon 5 1
c.463A4T
+c.464C4T
Unknown Exon 5 1
c.470T4A p.Val157Asp Exon 5 1
c.524G4A p.Arg175His Exon 5 4
c.527G4A p.Cys176Tyr Exon 5 1
c.588_609dup p.Glu204SerfsX12 Exon 6 1
c.614A4G p.Tyr205Cys Exon 6 1
c.637C4T p.Arg213X Exon 6 2
c.638G4T p.Arg213Leu Exon 6 1
c.659A4G p.Tyr220Cys Exon 6 2
c.685_686del p.Cys229TyrfsX10 Exon 7 1
c.713G4A p.Cys238Tyr Exon 7 1
c.722C4A p.Ser241Tyr Exon 7 1
c.724T4C p.Cys242Arg Exon 7 1
c.731G4A p.Gly244Asp Exon 7 1
c.733G4A p.Gly245Ser Exon 7 2
c.734G4A p.Gly245Asp Exon 7 1
c.743G4A p.Arg248Gln Exon 7 4
c.763A4T p.Ile255Phe Exon 7 1
c.705_713dup p.Tyr236_Cys238dup Exon 7 1
c.790_791del p.Leu264ThrfsX7 Exon 8 1
c.796G4A p.Gly266Arg Exon 8 1
c.817C4T p.Arg273Cys Exon 8 2
c.818G4A p.Arg273His Exon 8 2
c.824G4A p.Cys275Tyr Exon 8 1
c.844C4T p.Arg282Trp Exon 8 2
c.892G4T p.Gly298X Exon 8 1
aNumber of samples indicates the number of tumour samples in which each mutation
was found.
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sanalysis suggested that both TP53 and KRAS mutations were
independent predictive markers. Considering that alterations of
BRAF and PIK3CA/PTEN have been shown to result also in
resistance to anti-EGFR antibodies (Benvenuti et al, 2007; Frattini
et al, 2007; Cappuzzo et al, 2008b; Di Nicolantonio et al, 2008;
Jhawer et al, 2008; Perrone et al, 2009), we analysed the value of
TP53 mutation in the group of patients without detectable
mutations within KRAS, BRAF and PIK3CA. Among the 46 MCRC
patients without detectable KRAS mutation, we could analyse these
genes in 30 patients for whom sufficient tumour DNA was
available, and 24 of them had no detectable mutation of BRAF and
PIK3CA. In the subgroup of 24 patients without detectable
mutation within KRAS, BRAF and PIK3CA, we observed, in this
small sample, a trend but not significant difference between the
group of patients with (18) and without (6) TP53 mutation, in term
of CD (a TP53 mutation was found in 15 out of 19 (79%) patients
with CD as compared to 3 out of 5 (60%) with PD, P¼0.568) and
TTP (20 vs 12 weeks, P¼0.0931).
The association that we report between TP53 mutations and
better clinical outcome may appear unexpected because, in CRC,
most of studies have shown that TP53 mutations are associated
with a worse prognosis in stage II–III CRC patients (Westra et al,
2005). However, the predictive function of TP53 mutations in
MCRC patients treated with targeted therapies has not been so far
established. Indeed, the only previous study performed on MCRC
patients, which had evaluated the predictive value of TP53
mutations in the context of targeted therapies, concerns the anti-
vascular epidermal growth factor antibody bevacizumab, and no
correlation has been found between the TP53 status and the
clinical response (Ince et al, 2005). Considering that 63 out of 64
patients received irinotecan in combination with cetuximab in our
study, we cannot formally exclude that the TP53 status might
specifically influence the response to the conventional CT. Despite
the absence of control group in our work, this hypothesis seems
unlikely because it has been suggested in cellular models that TP53
status does not modulate the response to irinotecan (McDermott
et al, 2005).
In contrast, a recent study performed in cellular models has
suggested that TP53 status may influence the response to targeted
therapies (Kim et al, 2007). In a normal cell, the p53 protein acts
not only as a guardian of the genome, which is activated when
DNA damage occurs, but also as a policeman of oncogenes, which
becomes active when oncogenes are inappropriately activated, and
this activation induces apoptosis and/or senescence (Efeyan and
Serrano, 2007; Halazonetis et al, 2008). Moreover, alteration of the
p53 pathway has been reported to be observed in NSCLC with
activating EGFR mutations suggesting that p53 inactivation is
required to allow expansion of a cell with EGFR pathway activation
(Mounawar et al, 2007). Supporting this assumption, we found that
8 out of 9 (89%) tumours with an EGFR copy number increase
harboured a TP53 mutation whereas a TP53 mutation was found in
22 out of 38 (56%) tumours without detectable EGFR copy number
increase. Finally, it has been shown that p53-mediated growth
suppression is induced by PIK3CA signalling activation suggesting
that p53 acts as a brake for the PIK3CA transduction cascade
(Kim et al, 2007). Therefore, it is likely to speculate that activation
of the EGFR pathway will contribute to cancer and that anti-EGFR
antibodies will be efficient on tumour, only if p53 is inactivated.
This hypothesis is supported by our results showing that CD and
TTP were significantly increased in patients with TP53 mutation
treated with cetuximab-based CT. Recently, it has been shown in
cellular models that loss of p53 results into an EGFR promoter
induction (Bheda et al, 2008). Therefore, our results might be
explained not only by the fact that activation of EGFR is oncogenic
only if TP53 is inactivated, but also by the fact that inactivation
of TP53 could be one of the mechanisms leading to EGFR
activation.
In conclusion, our study suggests that TP53 genotyping could
have an additional value in MCRC patients without KRAS mutation
Table 3 Clinical response to cetuximab according to the TP53 status in
64 MCRC patients treated with cetuximab
Controlled disease
Complete
response
Partial
response
Stable
disease
Progressive
disease
TP53 non-mutated 0 4 6 13
TP53 mutated 2 10 17 12
Note: the TP53 status was assessed by sequencing analysis between exons 5 and 8.
P¼0.037 for TP53 mutations and CD vs PD.
Table 4 Clinical response to cetuximab according to the TP53 status in
the 46 MCRC patients without detectable KRAS mutation treated with
cetuximab
Controlled disease
Complete
response
Partial
response
Stable
disease
Progressive
disease
TP53 non-mutated 0 4 3 9
TP53 mutated 2 10 13 5
Note: the TP53 status was assessed by sequencing analysis between exons 5 and 8.
P¼0.008 for TP53 mutations and CD vs PD.
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Figure 1 Time to progression curves of MCRC patients treated with
cetuximab according to the TP53 genotype. (A) Patients without
detectable KRAS mutation. (B) Patients with KRAS mutation.
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sto optimise the selection of patients who should benefit from anti-
EGFR therapies. The relationship between TP53 status and
sensitivity to anti-EGFR should be investigated in cellular models
and the clinical relevance of our results should be confirmed on
larger MCRC series.
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